Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma

BACKGROUND. Alveolar soft part sarcoma (ASPS) is an exceedingly rare and orphan disease, without active drugs approved in the front line. Pazopanib and trabectedin are licensed for sarcoma treatment from second‐line, but very little and contradictory data are available on their activity in ASPS. Lac...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Stacchiotti, Silvia, Mir, Olivier, Le Cesne, Axel, Vincenzi, Bruno, Fedenko, Alexander, Maki, Robert G., Somaiah, Neeta, Patel, Shreyaskumar, Brahmi, Mehedi, Blay, Jean Y., Boye, Kjetil, Sundby Hall, Kirsten, Gelderblom, Hans, Hindi, Nadia, Martin‐Broto, Javier, Kosela, Hanna, Rutkowski, Piotr, Italiano, Antoine, Duffaud, Florence, Kobayashi, Eisuke, Casali, Paolo G., Provenzano, Salvatore, Kawai, Akira
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2017
Matèries:
Sarcomas
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5759809/
https://ncbi.nlm.nih.gov/pubmed/28754721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0161
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars